Obstructive Sleep Apnea (OSA) is a serious and widespread sleep disorder that affects 10% to 50% of the global population. It is characterized by repeated airway collapse during sleep, leading to oxygen deprivation, sleep fragmentation, and severe long-term health consequences. OSA is directly linked to increased risks of cardiovascular disease, stroke, hypertension, diabetes, depression, and even cognitive decline. Additionally, individuals with untreated OSA are up to five times more likely to suffer from heart attacks and have significantly higher rates of workplace and road accidents due to excessive daytime sleepiness. While CPAP therapy and other conventional treatments have been available for years, they come with significant limitations, including low patient compliance, discomfort, and high costs, leaving a vast number of patients without an effective, long-term solution.
